Free Trial
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

Galectin Therapeutics logo
$2.81 -0.01 (-0.35%)
(As of 10:54 AM ET)

About Galectin Therapeutics Stock (NASDAQ:GALT)

Key Stats

Today's Range
$2.76
$2.89
50-Day Range
$2.47
$3.00
52-Week Range
$1.55
$4.27
Volume
33,560 shs
Average Volume
145,310 shs
Market Capitalization
$176.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
34th Percentile Overall Score

GALT MarketRank™: 

Galectin Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 769th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Galectin Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($1.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Galectin Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Galectin Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    12.76% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 42.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Galectin Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Galectin Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.76% of the float of Galectin Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Galectin Therapeutics has a short interest ratio ("days to cover") of 42.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Galectin Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Galectin Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,846.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

  • Read more about Galectin Therapeutics' insider trading history.
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Stock News Headlines

Galectin Therapeutics (NASDAQ:GALT) Raised to Hold at StockNews.com
Galectin Therapeutics presents three abstracts at AASLD 2024 Liver Meeting
Breaking News: Tesla headed to $500…
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
Galectin Therapeutics Reports Increased Q3 Losses
See More Headlines

GALT Stock Analysis - Frequently Asked Questions

Galectin Therapeutics' stock was trading at $1.66 at the start of the year. Since then, GALT stock has increased by 72.3% and is now trading at $2.86.
View the best growth stocks for 2024 here
.

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Tuesday, August, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04.

Galectin Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.38%), Ikarian Capital LLC, State Street Corp (0.40%) and Soltis Investment Advisors LLC (0.23%). Insiders that own company stock include James C Czirr, Kary Eldred, Kevin D Freeman, Richard A Jr Zordani, Jack W Callicutt, Joel Lewis, Fund LP 10X and Elissa J Schwartz.
View institutional ownership trends
.

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GALT
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+290.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.51) per share

Miscellaneous

Free Float
29,686,000
Market Cap
$176.67 million
Optionable
Optionable
Beta
0.62

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:GALT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners